Immuno-Oncology gene signature generation with the nCounter PanCancer IO360 Panel

  • 12:00 pm (EST)


Inspired by systems biology approaches to cancer research, the nCounter® PanCancer IO360™ Panel gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. 

Join us LIVE to learn how TIS (Tumor Inflammation Score) was developed and validated, and hear from researchers about how the signatures are being used in the oncology field today. Ask your questions during the live Q&A.


  1. Praveer Sharma, NanoString Technologies, ‘An Introduction to the IO360 Panel and the nCounter Gene Exprerssion Analysis System’
  2. Marij J P Welters, Leiden University Medical Centre, ‘Deciphering the TME in HPV negative and HPV positive oropharyngeal squamous cell carcinoma (OPSCC)’
  3. Lakshimi Chandramohan, NeoGenomics, ‘Analytical Validation of the NanoString PanCancer IO360 Gene Expression Panel for Immuno-Oncology gene signature generation’.
  4. Benjamin Schattling, Universitätsklinikum Hamburg-Eppendorf , ‘Analysis of tumor and TME for more specific design of CARs against neuroblastoma’.

For Research Use Only.  Not for Use in Diagnostic Procedures.SpeakersPraveer Sharma
Field Application Scientist
NanoString Technologies

Marij J P Welters
Senior Researcher
Leiden University Medical Center (LUMC)

Marij Welters works at the Medical Oncology department of the Leiden University Medical Center (LUMC), Leiden, the Netherlands and was involved in the development of a therapeutic vaccine against the human papillomavirus type 16 (HPV16), a virus which causes anogenital and oropharyngeal (pre)malignant lesions. She is head of the immunomonitoring laboratory that performs the immunomonitoring of clinical trials using state-of-the art and complementary assays. She is chair of the European-based CIMT immunoguiding working group (CIP), which aims to establish high-quality immunomonitoring across the scientific field by supporting the concept of harmonization and promoting the technical validation of immunomonitoring assays. Next to this, she extended her research area to other tumor types (ovarian cancer, lung cancer, melanoma) and otherimmune cell types (including myeloid and regulatory cells) than the antigen-specific T cells and interrogated the immune landscape in the tumor in depth to develop rationale for combined immunotherapy.